[
    [
        {
            "time": "",
            "original_text": "天坛生物（600161）： 2021Q1业绩优异，浆源拓展和产能提升推动持续增长",
            "features": {
                "keywords": [
                    "天坛生物",
                    "2021Q1",
                    "业绩优异",
                    "浆源拓展",
                    "产能提升",
                    "持续增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物（600161）： 2021Q1业绩优异，浆源拓展和产能提升推动持续增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "东北证券维持天坛生物买入评级：新产能、新产品有序推进，业绩符合预期，目标价42.50元",
            "features": {
                "keywords": [
                    "东北证券",
                    "天坛生物",
                    "买入评级",
                    "新产能",
                    "新产品",
                    "有序推进",
                    "业绩符合预期",
                    "目标价"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东北证券维持天坛生物买入评级：新产能、新产品有序推进，业绩符合预期，目标价42.50元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "天坛生物(600161)：业绩符合预期 看好公司未来成长空间",
            "features": {
                "keywords": [
                    "天坛生物",
                    "业绩符合预期",
                    "未来成长空间"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物(600161)：业绩符合预期 看好公司未来成长空间",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]